You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信立泰(002294.SZ):SAL0114片獲得臨牀試驗批准通知書
格隆匯 02-25 20:40

格隆匯2月25日丨信立泰(002294.SZ)公佈,近日,公司收到國家藥品監督管理局核准簽發的《臨牀試驗批准通知書》,同意SAL0114片阿爾茲海默激越適應症開展臨牀試驗。

SAL0114片為複方製劑,系公司自主研發,已獲批可開展臨牀試驗的適應症為重度抑鬱,本次獲批可開展臨牀試驗的適應症為阿爾茲海默激越。

阿爾茲海默症(AD)是一種複雜的神經退行性疾病,是最常見的一種痴呆類型,其發病機制複雜且尚無定論,缺乏對疾病的病理進程的正確認知是導致尚無可以逆轉病程的藥物的根本原因。中國65歲及以上的阿爾茲海默症患病率在北方地區為4.2%,南方地區為2.8%。隨着年齡增高,患病率逐年上升。阿爾茲海默症的典型臨牀特徵為認知功能和執行能力的進行性下降,以及伴隨在整個疾病過程中的一系列神經精神症狀(NPS)。

在所有出現的NPS中,淡漠和抑鬱症狀是最常見的,但激越行為卻是傷害最大最困擾患者及家庭的行為之一。目前全球尚未有批准的藥物適應症為AD激越。SAL0114片若能研發成功並獲批上市,將進一步滿足潛在的臨牀需求,為患者提供新的用藥選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account